CLINICAL TRIALS PROFILE FOR EPANOVA
✉ Email this page to a colleague
All Clinical Trials for EPANOVA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00074542 ↗ | An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease | Completed | Tillotts Pharma AG | Phase 3 | 2002-09-01 | The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy. Patient safety and quality of life will also be monitored throughout the study. |
| NCT00613197 ↗ | EPANOVA in Crohn's Disease, Study 1 | Completed | Tillotts Pharma AG | Phase 3 | 2003-01-01 | The primary objective of this study is to assess the ability of EpanovaTM Soft Gelatin Capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (Crohn's Disease Activity Index CDAI < 150) in CD patients in whom remission, stable for at least three months and no longer than one year, has been induced by corticosteroids, azathioprine/6-MP, methotrexate, 5-ASA or antibiotics. Secondary objectives are to assess the: efficacy of Epanova versus placebo by Crohn's Disease Activity Index (CDAI), Investigator and Subject Global Ratings, employment status and use of CD related medical visits in subjects with CD in remission safety and tolerability of Epanova ability of Epanova to maintain the quality of life of CD patients in remission |
| NCT01208961 ↗ | Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation | Completed | Radiant Research | Phase 2 | 2010-09-01 | The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption. |
| NCT01208961 ↗ | Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation | Completed | AstraZeneca | Phase 2 | 2010-09-01 | The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat consumption. |
| NCT01242527 ↗ | Epanova® for Lowering Very High Triglycerides | Completed | AstraZeneca | Phase 2/Phase 3 | 2011-01-01 | The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EPANOVA
Condition Name
Clinical Trial Locations for EPANOVA
Trials by Country
Clinical Trial Progress for EPANOVA
Clinical Trial Phase
Clinical Trial Sponsors for EPANOVA
Sponsor Name
